• David Onions, PhD, has been promoted to the newly created position of chief medical officer of Invitrogen (Carlsbad, California). Onions joined Invitrogen in 2003. He was a founder and director of Q-One Biotech – which was acquired by Invitrogen through its purchase of BioReliance – where he served as BioReliance’s chief scientific officer. Onions also holds a chair in veterinary molecular virology at the University of Glasgow. Invitrogen provides life science technologies for disease research, drug discovery and commercial bioproduction. Its own R&D efforts are focused on various areas of biological discovery, including functional genomics, proteomics, bioinformatics and cell biology.

• Dr. David Weissberg was appointed CEO of Molecular Diagnostics (Chicago), replacing Denis O’Donnell, MD, who voluntarily stepped down as a director, president and CEO as part of a company restructuring. Weissberg has helped to build several medical practice and service-related businesses and is a major investor in Molecular Diagnostics. Molecular Diagnostics develops cancer-screening systems, which can be used in a laboratory or at the point of care.